This article was originally published in The Gray Sheet
Executive SummaryExpanded labeling approval for the Targis system includes a claim for treatment of the obstruction in the urethra caused by benign prostatic hyperplasia, the firm reports Aug. 7. No similar devices have been approved for this indication, the firm states. The system is currently approved for treatment BPH symptoms, such as frequent urination. Separately, the company reports revenues of $11.2 mil. for fiscal year 1998 ending June 30 compared to $5.5 mil. one year ago. Urologix books a larger net loss in FY 1998 ($15 mil.) versus its net loss in the year prior period ($8.2 mil.)
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.